(WISH) — Novo Nordisk, the maker of the weight-loss drug Wegovy, has filed a lawsuit against Indianapolis-based pharmaceutical giant Eli Lilly & Co., the manufacturer of Zepbound, accusing the company of running deceptive advertising.

The lawsuit targets ads claiming patients using Zepbound lost more weight than those taking Wegovy. Novo Nordisk contends the ads are misleading because they compare the highest doses of Zepbound with the lowest doses of Wegovy.

Novo Nordisk is demanding that Lilly pull the current ads and replace them with accurate information.

While Zepbound and Wegovy contain different active ingredients, both work similarly on the body to promote weight loss.

Adding to the complexity, Wegovy and Ozempic are the same medication. Zepbound is slightly different but identical to Mounjaro. All four drugs belong to the GLP-1 class of medications.

This story, based on a CNN TV script, was formatted for WISHTV.com using AI-assisted tools. Our editorial team reviews and edits all content published to ensure it meets our journalistic standards for accuracy and fairness.